0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aim: To examine the effectiveness of eribulin mesylate for metastatic breast cancer post cyclin-dependent kinase inhibitor (CDKi) 4/6 therapy. Materials & methods: US community oncologists reviewed charts of patients who had received eribulin from 3 February 2015 to 31 December 2017 after prior CDKi 4/6 therapy and detailed their clinical/treatment history, clinical outcomes (lesion measurements, progression, death) and toxicity. Results: Four patient cohorts were created according to eribulin line of therapy: second line, third line, per US label and fourth line with objective response rates/clinical benefit rates of 42.2%/58.7%, 26.1%/42.3%, 26.7%/54.1% and 17.9%/46.4%, respectively. Median progression-free survival/6-month progression-free survival (79.5% of all patients censored) by cohort was: 9.7 months/77.3%, 10.3 months/71.3%, not reached/70.4% and 4.0 months/0.0%, respectively. Overall occurrence of neutropenia = 23.5%, febrile neutropenia = 1.3%, peripheral neuropathy = 10.1% and diarrhea = 11.1%. Conclusion: Clinical outcome and adverse event rates were similar to those in clinical trials and other observational studies. Longer follow-up is required to confirm these findings.

          Related collections

          Author and article information

          Journal
          Future Oncol
          Future oncology (London, England)
          Future Medicine Ltd
          1744-8301
          1479-6694
          December 2019
          : 15
          : 34
          Affiliations
          [1 ] Yale Cancer Center, Yale Medical School, New Haven, CT 06510, USA.
          [2 ] Cardinal Health Specialty Solutions, Dublin, OH 43017, USA.
          [3 ] Formerly with Eisai, Inc., US Health Economics and Outcomes Research and Real World Evidence, Woodcliff Lake, NJ 07677, USA.
          [4 ] Formerly with Eisai, Inc., Medical Affairs, Woodcliff Lake, NJ 07677, USA.
          [5 ] Eisai, Inc., US Health Economics and Outcomes Research and Real World Evidence, Woodcliff Lake, NJ 07677, USA.
          Article
          10.2217/fon-2019-0537
          31660764
          9e2de53a-77a8-4c5c-aa5d-7ae39a51334b
          History

          palliative/end-of-life care,outcomes research,hormonal therapy,chemotherapy,breast,real-world evidence

          Comments

          Comment on this article